Copenhagen University
RhoVac appoints new Chief Development Officer
Rhovac’s drug candidate, RV001, is being developed with the goal of targeting and destroying cancer cells with the potential...
2cureX tops off eventful first half of 2019 with addition of expert clinician as Chief Medical Officer
2019 has seen 2cureX reaping the benefits of...
